Gynecomastia refers to an enlargement of the male breast caused by benign proliferation of the glands ducts and stromal components including fat. It is the most common form of breast swelling seen in adolescent males. During pubertal development, gynecomastia can develop as a result of transient relative imbalances between androgens and estrogens. Pubertal gynecomastia is self-limited in 75 to 90% of adolescents and regresses over 1 to 3 years. However it may cause significant psychological stress and depression in adolescents. For boys with persistent gynecomastia that is causing substantial tenderness or embarrassment a tailored approach of close follow-up and use of anti-estrogen drugs may be recommended. These drugs block the effects of estrogens in the body and can reduce the size of the breasts somewhat. It appears that pharmacological therapy of persistent adolescent gynecomastia is reasonable effective if given early in the course of the disease and more successful in cases with small or moderate breast enlargement. However, neither of these drugs is universally approved for the treatment of gynecomastia because the risks and benefits have not been studied completely. Surgical approach may be needed under special conditions for cosmetic reasons. In this update, we review the different published trials for managing adolescent gynecomastia.
Soliman AT, De Sanctis V, Yassin M. Management of Adolescent Gynecomastia: An Update. Acta Bio Med [Internet]. 2017Aug.23 [cited 2021Mar.9];88(2):204-13. Available from: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/6665
The Authors confirm that neither the manuscript nor any part of it has been published or is under consideration for publication elsewhere. The same Authors assign all rights, including but no limiteded to the copyright, for the present manuscript to Acta Biomedica upon its acceptance for publication. When the manuscript is accepted, the Editorial office of Acta Biomedica inform about the Author reported in the manuscript . If no reply will be received, Acta Biomedica Editorial office will apply the rule “no response means implied consent” and it will proceed with the publication.
Accepted papers become the permanent property of ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA and no part may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of both the author and the publisher.